SCHEMBL5359174

SCHEMBL5359174

CCOC(=O)c1cc2ccc(C)c(Cl)c2n1C(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.37
SERPINE1 P05121 1/20 0.35
PCSK9 Q8NBP7 1/20 0.35
NOD2 Q9HC29 2/20 0.34
NOD1 Q9Y239 2/20 0.34
AAK1 Q2M2I8 1/20 0.34
BRD4 O60885 2/20 0.34
ABCB1 P08183 1/20 0.34
TSHR P16473 2/20 0.33
ALDH1A1 P00352 4/20 0.33
MAPT P10636 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
RAB9A P51151 1/20 0.33
DHODH Q02127 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359170 1.00 SYK (0.37) SYKSERPINE1PCSK9NOD2NOD1
SCHEMBL5357460 0.90 SYK (0.39) SYKSERPINE1PCSK9AAK1BRD4
SCHEMBL5357465 0.90 SYK (0.39) SYKSERPINE1PCSK9AAK1BRD4
SCHEMBL5361547 0.89 SYK (0.37) SYKSERPINE1PCSK9AAK1ABCB1
SCHEMBL5361545 0.89 SYK (0.37) SYKSERPINE1PCSK9AAK1ABCB1
SCHEMBL27524596 0.89 PCSK9 (0.36) SYKSERPINE1PCSK9AAK1BRD4
SCHEMBL5356061 0.88 SYK (0.37) SYKSERPINE1PCSK9NOD2NOD1
SCHEMBL4044170 0.88 AAK1 (0.38) SYKSERPINE1PCSK9AAK1BRD4
SCHEMBL5359194 0.88 AAK1 (0.38) SYKSERPINE1PCSK9AAK1BRD4
SCHEMBL5356065 0.88 SYK (0.37) SYKSERPINE1PCSK9NOD2NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253281-B2 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
US-20070106076-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles BENTLEY JONATHAN M 2007-05-10 US disclosed
US-20050239789-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles BENTLEY JONATHAN M 2005-10-27 US disclosed
EP-1325008-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-10-05 EP disclosed
US-6933387-B2 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles HOFFMANN-LA ROCHE INC. (US) 2005-08-23 US disclosed
US-20030216401-A1 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles F. HOFFMANN-LA ROCHE AG (CH) 2003-11-20 US disclosed
EP-1325008-A1 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-07-09 EP disclosed
US-20020035110-A1 Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) 2002-03-21 US disclosed
WO-2002010169-A1 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239789-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles GPR119, INSR, GIPR SYK 3413/4885SERPINE1 3768/4885PCSK9 820/4885
US-20030216401-A1 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles GPR119, INSR, IRS1 SYK 4160/4885SERPINE1 2358/4885PCSK9 1121/4885
US-20070106076-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles GPR119, INSR, GIPR SYK 3413/4885SERPINE1 3768/4885PCSK9 820/4885
US-20020035110-A1 Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles GPR119, HTR1D, HTR1A SYK 3324/4885SERPINE1 2396/4885PCSK9 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.